Since years, cannabis companies have treated the federal rescheduling of marijuana as an end. This isn’t the case.
Cannabis’s reclassification to Schedule III, will provide some tax benefits and open a new market pathway, but the result won’t be a unified, legitimate industry—it’ll be a split one: two systems, two rulebooks and no clear bridge between them. Many people believe that the regulatory fog surrounding cannabis will disappear once it leaves Schedule I. The industry will then operate as any other legit sector. But in reality, the outcome will be less dramatic—and more complicated.
It’s important to mention a popular argument in the industry: The fog won’t lift until cannabis has been descheduled and not rescheduled. It won’t resemble more familiar industries such as alcohol or tobacco until it is removed from the Controlled Substances Act. To make this happen would take a highly political act from Congress, which today isn’t on the agenda. Rescheduling is the only option for now.
It could be that the fog is just getting thicker for a little while. It is unlikely that the Schedule III classification will unify cannabis. This will formalize a division between cannabis operators that want to be Schedule III compliant, and those operating within state regulation systems. This is a fundamentally different model, with different market, distribution, and standards. It’s not possible to run both simultaneously.
And without new federal legislation—not merely reclassification—that policy gap’s unlikely to be resolved soon.
State markets would continue to function largely as they currently do if cannabis was moved from Schedule II to Schedule III, without any new federal legislation or significant rulemaking. Regulators—particularly the DEA—historically avoid sweeping changes that expand or legitimize emerging industries. The supply chain is intact in practice: Growers grow cannabis under state licenses; manufacturers make branded products; and dispensaries keep selling their products through state-regulated system.
There is no real change in federal classification. This tension is not going anywhere.
Schedule III is most effective in the pharmaceutical industry, a totally new sector that operates within federal law.
Schedule III substances are governed by the Controlled Substances Act and move through tightly regulated pharmaceutical supply chains—very different from the state cannabis model. Production is regulated and carries quotas and security requirements.
The dispensaries do not fit within this framework. Dispensaries never fit into that framework.
In the US, cannabinoid-compliant products are more likely to flow through existing healthcare channels. This includes pharmacies as well as compounding pharmacies. Compounding pharmacists prepare customized medication by mixing specific ingredients according to the strength, dosage, and form prescribed. US controlled substances tend to be prescribed, not retailed. Consider prescriptions and not marijuana sellers.
So, the real question for Schedule III cannabis is: Does the plant move into a prescription model tailored to each patient—or stay a dispensary product? It would likely follow a physician–pharmacy model, but without the mass prescription dynamics of the pill mill era, leaning instead toward individualized treatment.
With limited federal guidance and low physician familiarity, pharmaceutical compounding may become the bridge—patient-specific cannabinoid formulations prepared by pharmacies using regulated inputs.
Schedule III substances may be approved medications or pharmacy-prepared formulations. On many international markets physicians prescribe cannabinoid treatments that are patient specific, which pharmacies then prepare with regulated ingredients. These magistral preparations—common across Europe, including in Germany and Netherlands—operate within pharmaceutical systems, not retail dispensaries.
In the US, a similar path could be developed, in which physicians prescribe, pharmacists compound and producers who comply with federal regulations supply inputs. That model would look far more like international medical frameworks than the American dispensary system—creating a parallel pharmaceutical cannabis market alongside existing state retail channels, with open questions about overlap and participation.
US operators should not overlook the global dimension. Many cannabis companies abroad already function within regulatory systems resembling a federally controlled Schedule III framework—particularly across Europe and Latin America, where medical regimes require pharmaceutical-grade standards, controlled substance tracking and government-authorized export structures.
These operators have become accustomed to FDA and DEA oversight. They could have an advantage in developing a supply chain for cannabinoid products that is compliant with federal law.
This advantage has limitations. It is not enough to be familiar with the regulated markets in order to gain access. The US systems are highly regulated and tightly licensed, and they have a siloed structure. International operators could find an opportunity through a federal channel. However, the state market will be largely off-limits unless there is significant restructuring at either federal or state levels.
The most immediate consequence of rescheduling, for both state and federally compliant businesses, isn’t structural—it’s financial. For the first time since decades, tax Section 280E wouldn’t apply to cannabis businesses. This alone would improve margins, change valuations and bring financial practices closer to those of traditional industries.
It’s not all the same.
Many large companies have deferred 280E liability or challenged it, considering them future obligations instead of current payments. Others—especially smaller businesses—have absorbed those costs annually. Relief could improve their cash flow and financial stability.
280E is also being challenged by new legal theories, but these are complex and require a lot of information. The broader point is simple: The industry’s tax burden has never been consistent—and reform won’t change that overnight.
What will all this lead to? The state cannabis industry will continue to operate largely as it does today. Consumers are served through dispensaries, and supply chains that are vertically integrated. Meanwhile, federally compliant Schedule III cannabinoid medicines may emerge through controlled pharmaceutical channels—manufacturers, physicians and pharmacies.
There are two regulatory logics.
Two different supply chains.
Two markets.
Schedule III might not lead to the future many had envisioned but will certainly set off the industry on a new path. Cannabis can be added to the list of unknowns.
This article was first published on the printed edition of Cannabis Now Magazine, Issue 53 on 20 April 2026. (Just a few weeks before the April 23 rescheduling).